BackInnoCan Pharma Overview

InnoCan Pharma Current Assets

Track InnoCan Pharma's current assets ($9.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$9.75M
↓ 10.82% YoYΔ $-1.18M vs prior year quarter

Peer trimmed avg / median

Loading

InnoCan Pharma Current Assets History

Loading

InnoCan Pharma vs. peers: Current Assets Comparison

Loading

InnoCan Pharma Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

InnoCan Pharma (INNPF) FAQ

The latest current assets for INNPF is $9.8M as of June 2026. That compares with $11M in the prior-year period — down 10.8% year over year. Investors often review this figure alongside InnoCan Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, INNPF's current assets moved from $11M to $9.8M — a 10.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in InnoCan Pharma's operating scale or balance-sheet position.

A current assets figure of $9.8M for INNPF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting INNPF's current assets ($9.8M), review year-over-year change from $11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.